Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-20T07:46:22.620Z Has data issue: false hasContentIssue false

Between Scylla and Charybdis: Where does the treatment of Addison's disease in late-life depression go first?

Published online by Cambridge University Press:  23 March 2020

S. Petrykiv*
Affiliation:
GGZ Friesland, Emergency Psychiatry, Leeuwarden, Netherlands
M. Arts
Affiliation:
UMC Groningen, Old Age Psychiatry, Groningen, Netherlands
L. de Jonge
Affiliation:
UMC Groningen, Epidemiology, Groningen, Netherlands
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Older adults with adrenocortical insufficiency, including Addison's disease (AD), are at an increased risk for developing late-life depression. Treatment of AD with glucocorticoid replacement therapy may exacerbate depressive symptoms and may complicate treatment of late-life depression.

Objectives

To present a case with algorithm of decision-making in a particular case of glucocorticoid induced depression in patient with syndrome of Addison.

Aims

To report a case-study, describing treatment of Addison's disease in LLD.

Methods

A case report is presented and discussed, followed by a literature review.

Results

A 77-year-old female, diagnosed with Addison's disease, was referred with persistent fatigue, weakness, weight loss, sleep disturbances, and depressive symptoms over the previous 6 months. She was taken losartan 100 mg/day, zolpidem 10 mg/day, fludrocortisone 100 μg/day, and hydrocortisone 35 mg/day. There was no personal or family history of psychiatric problems. Clinical examination was normal aside from skin hyperpigmentation. After initial minimal dose reduction of glucocorticoids, Addison's disease remained under control. One week later, her depressive symptoms disappeared without administration of antidepressants.

Conclusion

The association between glucocorticoid replacement therapy and late-life depression is not well understood. The current case shows that treatment of glucocorticoid-induced depression in subjects with Addison's disease is achievable by minimal adjustments in glucocorticoid regiment. However, collaboration with endocrinology is of vital importance to prevent an Addison's crisis. Pharmacokinetic dose-finding studies are required to find optimal glucocorticoid adjustment strategy.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV389
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.